In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

The free consultation period for this content is over.

It is now only available year-round to HFA Silver & Gold Members, Fellows of the ESC and Young combined Members

Long-term effects of patiromer for hyperkalaemia treatment in patients with HFrEF and diabetic nephropathy on RAASi

Session Poster Session 1

Speaker Bertram Pitt

Congress : Heart Failure 2017

  • Topic : coronary artery disease, acute coronary syndromes, acute cardiac care
  • Sub-topic : Coronary Artery Disease (Chronic)
  • Session type : Poster Session
  • FP Number : P285

Authors : B Pitt (Ann Arbor,US), D Garza (Redwood City,US), R Zawadzki (Redwood City,US), A Romero (Redwood City,US), A Conrad (Redwood City,US), M Lainscak (Murska Sobota,SI)

B Pitt1 , D Garza2 , R Zawadzki3 , A Romero4 , A Conrad4 , M Lainscak5 , 1University of Michigan - Ann Arbor - United States of America , 2Relypsa, Inc., Clinical Development - Redwood City - United States of America , 3Relypsa, Inc., Biometrics - Redwood City - United States of America , 4Relypsa, Inc., Medical Affairs - Redwood City - United States of America , 5General Hospital Murska Sobota - Murska Sobota - Slovenia ,

European Journal of Heart Failure ( 2017 ) 19 ( Suppl. S1 ), 55

Purpose: Renin angiotensin aldosterone system inhibitors (RAASi) are indicated in patients (pts) with heart failure with reduced ejection fraction (HFrEF). RAASi increase the risk of hyperkalaemia (HK), particularly in pts with chronic kidney disease (CKD) and/or diabetes, and are often discontinued in HFrEF pts. Patiromer, a nonabsorbed, sodium-free potassium (K+)-binder, was previously shown in the AMETHYST-DN study to lower serum K+ (s-K+) through 52 weeks in pts with HK and diabetic nephropathy on RAASi. In this post-hoc analysis we examined the effects of patiromer on s-K+ in HK patients with HFrEF. Methods: Patients with type-2 diabetes, CKD, and HK (baseline s-K+ >5.0–<6.0 mmol/L) were randomized to patiromer starting doses of 8.4–33.6 g/day, divided twice daily. All pts were receiving RAASi during study treatment. Changes in mean s-K+ from baseline through Week 52 were evaluated in the subgroup with HFrEF (EF =40%). Results: Of 306 randomized pts, 26 had HFrEF (100% Caucasian, 62% male, 69% =65 yr of age, mean [SD] EF: 37 [3]%, mean [SD] eGFR: 43.6 [17.7] mL/min/1.73m2. Mean s-K+ was reduced to <5.0 mmol/L at the first post-baseline visit (day 3, 48 hr after first patiromer dose) through Week 52 and stopping patiromer led to a rise in s-K+ (Table). No pts discontinued due to high s-K+. Patiromer was generally well tolerated, with 17 (65%) pts reporting =1 adverse event (AE) during the study. Mild or moderate gastrointestinal AEs were the most common class (occurring in 2 pts) of patiromer-related AEs, with abdominal discomfort, nausea and vomiting each occurring in 1 pt. No pts had s-K+ <3.5 mmol/L, 1 pt had serum magnesium <1.4 mg/dL (<0.57 mmol/L), and there were no reports of edema. From a baseline mean (SE) of 151.1 (2.0)/90.8 (2.1) mmHg, systolic/diastolic BP decreased by 17.0 (2.2)/ 16.2 (2.3) mmHg at Week 52. Conclusions: Patiromer decreased s-K+ through 52 weeks in HFrEF pts with HK and diabetic nephropathy. These post-hoc results, suggesting that patiromer allows continuous management of HK in HFrEF pts on RAASi, require further prospective evaluation.

Baseline (n=26)

5.23 (0.5)

Day 3 (n=26)

Δ from baseline

4.82 (0.07)

−0.41 (0.07)

Week 4

Δ from baseline

4.60 (0.08)

−0.58 (0.09)

Week 24 (n=19)

Δ from baseline

4.62 (0.06)

−0.55 (0.09)

Week 52 (n=19)

Δ from baseline

4.57 (0.08)

−0.61 (0.07)

End of treatment (EOT) (n=20)

4.57 (0.10)

Follow-up Day +28 (n=17)

Δ from EOT

4.97 (0.10)

+0.49 (0.08)

Values are mean (SE) in mmol/L.

Based on your interests

Members get more

Join now
  • 1ESC Professional Members – access all resources from ESC Congress and ESC Asia with APSC & AFC
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s congress resources
  • 3Under 40 or in training - with a Combined Membership, access resources from all congresses
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are